Delivery Order SPE2DB20D1109-SPE2DB25FP49F
- Not listed
- The Defense Logistics Agency awarded a $17,929.57 delivery order to AmerisourceBergen Drug Corp on September 17, 2025, for Dupixent 200 mg/1.14 mL pen injectors. This is a firm fixed-price, non-set-aside delivery order with a completion date of September 18, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a monoclonal antibody used to treat conditions including moderate-to-severe eczema, asthma, and chronic rhinosinusitis, making...
- The Defense Logistics Agency awarded a delivery order valued at $33,274.72 to AmerisourceBergen Drug Corp for the supply of Dupixent 200 mg/1.14 mL pen injectors. This competitively awarded, firm fixed-price contract was executed on August 11, 2025, with an ultimate completion date of August 12, 2025, and does not include a set-aside designation. Performance will occur at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a biologic medication...
- The Defense Logistics Agency awarded a delivery order valued at $10,813.19 to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml pen injectors on August 13, 2025, with an ultimate completion date of August 14, 2025. This is a firm fixed price, competitively awarded delivery order with no set-aside designation. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. Dupixent is a biologic medication used to treat moderate-to-severe eczema, asthma, and...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for $17,844.05 to supply Dupixent 300 mg/2 ml pen injectors, with a completion deadline of September 8, 2025. This non-set-aside, competitively awarded contract reflects firm fixed pricing and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a biologic medication used to treat eczema, asthma, and other inflammatory conditions, demonstrating...
- The Defense Logistics Agency awarded a delivery order valued at $103,490.97 to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml pen injectors on July 29, 2025, with an ultimate completion date of July 30, 2025. This is a firm fixed-price, competitively awarded contract with no set-aside designation. The pharmaceutical product will be delivered to the contractor's facility in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. Dupixent is a biologic...
- The Defense Logistics Agency awarded a delivery order valued at $17,474.93 to AmerisourceBergen Drug Corp on July 14, 2025, for the supply of Dupixent 300 mg/2 mL pen injectors. This is a firm fixed price, non-set-aside contract with an ultimate completion date of July 15, 2025, with performance taking place at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a biologic medication used to treat various allergic and inflammatory conditions, including...
- The Defense Logistics Agency awarded a delivery order valued at $45,354.18 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 mL pen injectors on April 23, 2025, with completion expected by April 24, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at the contractor's corporate office in Conshohocken, Pennsylvania. Dupixent is a biologic medication used to treat severe eczema, asthma, and other allergic...
- The Defense Logistics Agency awarded a $40,995.34 delivery order to AmerisourceBergen Drug Corp on April 25, 2025, for the supply of Dupixent 300 mg/2 ml pen injectors. This competitively awarded, non-set-aside contract specifies firm fixed pricing with an ultimate completion date of April 28, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a biologic medication used to treat moderate-to-severe atopic dermatitis,...
- The Defense Logistics Agency awarded a $17,791.36 delivery order to AmerisourceBergen Drug Corp on June 26, 2025, for the supply of Dupixent 300 mg/2 mL pen injectors. This is a firm fixed-price, non-set-aside contract with a completion date of June 27, 2025, and performance to be fulfilled at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a biologic medication commonly used to treat moderate-to-severe eczema, asthma, and chronic...
- The Defense Logistics Agency awarded a delivery order valued at $117,847.83 to AmerisourceBergen Drug Corp on August 29, 2025, for the supply of Dupixent 300 mg/2 mL pen injectors. This competitively awarded, non-set-aside contract carries a firm fixed price structure with an ultimate completion date of September 2, 2025, and will be performed at AmerisourceBergen's Corporate Office location in Conshohocken, Pennsylvania. Dupixent is a biologic medication commonly prescribed for conditions...
- SPE2DB20D1109Indefinite Delivery Contract
- SPE2DB20D1109-SPE2DB25FP49FDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $10,986.42 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 ml pen injectors. This is a firm fixed price, competitively awarded delivery order with a completion date of July 31, 2025. The contract carries no set-aside designation and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. Dupixent is a biologic medication used to treat conditions such as atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps, representing a critical pharmaceutical supply for military healthcare systems. This delivery order is issued under AmerisourceBergen Drug Corp's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a comprehensive global pharmaceutical support vehicle valued at $999.99 billion through December 2026. As a major pharmaceutical distributor, AmerisourceBergen Drug Corp serves as a prime vendor for the Defense Health Agency and other federal healthcare systems, supplying an extensive portfolio of brand-name and generic medications, specialty drugs, and medical supplies across multiple therapeutic domains. The company's consistent receipt of competitive federal awards demonstrates its capability to meet stringent military medical procurement requirements.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $11.0k | 7/30/25 |